New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

West Pharmaceutical Services, Inc.

WST

Healthcare Medical Instruments & Supplies

West Pharmaceutical Services, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 billion, up 6.25% from fiscal 2024.

Revenue
+8.69%
EPS
+57.3%
Free cash flow
+12.3%
Total debt
+0.10%

Quarter to September 2026, against a year earlier

390.56 6.13 −1.55%

After hours trading: 390.30, down 0.07%, last trade 5:54pm Eastern.

Market cap
$27.6B
P/E
43.5×
Fwd P/E FY26e
44.6×
Dividend yield
0.24%
F-score
8/9
ROIC
18.0%
Net debt / EBITDA
−0.8×
Payout ratio
0.1×

West Pharmaceutical Services, Inc. (WST) revenue by segment, product and region

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.